Newsroom

Download PDF Extends Cash Runway to Fund Planned Operations into the Third Quarter of 2019 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 4, 2018– AVEO Oncology (NASDAQ:AVEO) today announced a six-month extension to the interest only period under its existing amended and restated loan and security agreement with Hercules Capital, Inc. (Hercules). The extension was granted as a result of achieving certain predefined

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 20, 2018– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 28, 2018 at 2:30 p.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel. A live webcast of the presentation can be accessed by visiting

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 15, 2018– AVEO Oncology (NASDAQ: AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the commercial launch and reimbursement in Germany of FOTIVDA® (tivozanib) as a first line treatment of adult patients with advanced renal cell carcinoma (RCC). In the European Union, Norway and Iceland, tivozanib is indicated for the first line

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 9, 2018– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2018 and provided a business update. “The recent announcement of positive topline results from the Phase 3 TIVO-3 study in renal cell carcinoma is transformative for AVEO, and the next step of an ongoing, multi-year effort to ensure tivozanib (FOTIVDA®)

Download PDF – First and Only Positive Phase 3 Study in Third- and Fourth-Line RCC – – Primary Endpoint Shows 44% Improvement in Median PFS and 26% Reduction in Risk of Progression or Death (HR=0.74, p=0.02) for Tivozanib Compared to Sorafenib – – Data for Secondary Endpoint of Overall Survival Not Yet Mature;Final Analysis Planned

Download PDF Tivozanib-Nivolumab Combination Continues to Demonstrate Favorable Efficacy and Safety Data Presented at the European Society of Medical Oncology (ESMO) 2018 Annual Congress CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England–(BUSINESS WIRE)–Oct. 22, 2018– AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced the presentation of updated interim results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 9, 2018– AVEO Oncology (NASDAQ:AVEO) today announced that updated interim data from the Phase 2 portion of the TiNivo trial of tivozanib and nivolumab (OPDIVO®) in advanced renal cell carcinoma will be presented at the European Society of Medical Oncology (ESMO) 2018 Annual Congress being held October 19-23, 2018 in Munich, Germany. The TiNivo study is a

Download PDF – Analysis Initiated on the Unanimous Recommendation of the TIVO-3 Study Independent Steering Committee – – Company Expects to Report Topline Results in Approximately 6 Weeks – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 1, 2018– AVEO Oncology (NASDAQ: AVEO) today announced that it has initiated topline analysis of the phase 3 TIVO-3 clinical trial on the unanimous recommendation of the independent TIVO-3